Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.

[1]  Bahar Yilmazel,et al.  Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma With Comprehensive Genomic Profiling. , 2022, The Journal of molecular diagnostics : JMD.

[2]  D. Smith,et al.  FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. H. Klotz,et al.  Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. , 2022, The Lancet. Oncology.

[4]  H. Nishiyama,et al.  FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Theodorescu,et al.  Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling , 2021, Cancers.

[6]  Joon-Oh Park,et al.  Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study , 2021, Cancer discovery.

[7]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.

[8]  Carlos L. Arteaga,et al.  FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[9]  C. Britten,et al.  A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer , 2021, Investigational New Drugs.

[10]  Carlos L. Arteaga,et al.  Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer , 2021, Clinical Cancer Research.

[11]  N. Agarwal,et al.  TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Hui Zhan,et al.  The Role of FGFR3 in the Diagnosis and Treatment of Bladder Cancer: A Review , 2021, Cancer Plus.

[13]  T. Powles,et al.  Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. , 2021, The New England journal of medicine.

[14]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[15]  M. Berger,et al.  Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations , 2021, JCO precision oncology.

[16]  Hui-Zi Chen,et al.  Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance , 2020, British Journal of Cancer.

[17]  Hiroshi Sootome,et al.  Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors , 2020, Cancer Research.

[18]  Jian Q. Feng,et al.  FGF/FGFR signaling in health and disease , 2020, Signal Transduction and Targeted Therapy.

[19]  M. Galsky,et al.  Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. , 2020, European urology.

[20]  R. Garje,et al.  Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer , 2020, The oncologist.

[21]  Wanlong Ma,et al.  FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. , 2020 .

[22]  R. Wynn,et al.  INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models , 2020, PloS one.

[23]  T. Powles,et al.  FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations. , 2020 .

[24]  Jun Zhu,et al.  Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. , 2019, European urology.

[25]  L. Marandino,et al.  Erdafitinib for the treatment of urothelial cancer , 2019, Expert review of anticancer therapy.

[26]  G. Curigliano,et al.  Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 , 2019, Annals of Oncology.

[27]  S. Park,et al.  Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. , 2019, The Lancet. Oncology.

[28]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[29]  J. Bellmunt,et al.  Management of metastatic bladder cancer. , 2019, Cancer treatment reviews.

[30]  A. Bardia,et al.  Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer , 2019, Nature Communications.

[31]  D. Zopf,et al.  Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models , 2019, International journal of cancer.

[32]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[33]  Mauro A. A. Castro,et al.  A Consensus Molecular Classification of Muscle-invasive Bladder Cancer , 2019, European urology.

[34]  V. Mazzaferro,et al.  Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma , 2018, British Journal of Cancer.

[35]  R. Seiler,et al.  Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when? , 2018, World Journal of Urology.

[36]  R. Huddart,et al.  Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  M. Maio,et al.  Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Hai-ge Chen,et al.  Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy , 2018, EBioMedicine.

[39]  R. Berger,et al.  Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. , 2018, Cancer discovery.

[40]  P. Hegde,et al.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.

[41]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[42]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[43]  A. Tolcher,et al.  A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours , 2017, British Journal of Cancer.

[44]  M. Kohli,et al.  Management of Muscle‐Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer , 2017, Mayo Clinic proceedings.

[45]  A. Drilon,et al.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance , 2017, Nature Reviews Clinical Oncology.

[46]  Roman K. Thomas,et al.  Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer , 2017, Clinical Cancer Research.

[47]  R. Bernards,et al.  A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. , 2017, European urology.

[48]  P. V. van Dam,et al.  FGFR a promising druggable target in cancer: Molecular biology and new drugs. , 2017, Critical reviews in oncology/hematology.

[49]  C. Murray,et al.  Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor , 2017, Molecular Cancer Therapeutics.

[50]  N. Turner,et al.  Advances and challenges in targeting FGFR signalling in cancer , 2017, Nature Reviews Cancer.

[51]  J. Datta,et al.  Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398 , 2017, Molecular Cancer Therapeutics.

[52]  Manuel Hidalgo,et al.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[54]  Massimo Cristofanilli,et al.  Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application , 2016, Oncotarget.

[55]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[56]  E. Plimack,et al.  A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157 , 2016, Clinical Cancer Research.

[57]  M. Katoh.  FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review) , 2016, International journal of molecular medicine.

[58]  A. N. Meyer,et al.  Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation , 2016, Molecular Cancer Research.

[59]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[60]  A. N. Meyer,et al.  Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. , 2015, Cytokine & growth factor reviews.

[61]  R. Kurzrock,et al.  Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications , 2015, Cancer and Metastasis Reviews.

[62]  R. Shah,et al.  Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit , 2015, Drug Safety.

[63]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[64]  P. Coveney,et al.  The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study , 2015, EBioMedicine.

[65]  A. Iavarone,et al.  Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.

[66]  Jesse K. Placone,et al.  Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization. , 2015, Biophysical journal.

[67]  M. Milowsky,et al.  Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. , 2014, European journal of cancer.

[68]  K. Morikami,et al.  The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor , 2014, Molecular Cancer Therapeutics.

[69]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[70]  C. Porta,et al.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[71]  Wei Zhang,et al.  Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours , 2014, The Journal of pathology.

[72]  The Cancer Genome Atlas Research Network.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[73]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[74]  A. Ashworth,et al.  Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. , 2013, Cancer discovery.

[75]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[76]  Thomas Bachelot,et al.  Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer , 2013, Clinical Cancer Research.

[77]  R. Stevens,et al.  Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT/A) , 2013, PLoS pathogens.

[78]  M. Mohammadi,et al.  Exploring mechanisms of FGF signalling through the lens of structural biology , 2013, Nature Reviews Molecular Cell Biology.

[79]  L. Kiemeney,et al.  Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.

[80]  M. Nykter,et al.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.

[81]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[82]  Pascal Furet,et al.  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.

[83]  G. Sonpavde,et al.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  M. Knowles,et al.  Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo , 2010, British Journal of Cancer.

[85]  B. Trueb.  Biology of FGFRL1, the fifth fibroblast growth factor receptor , 2011, Cellular and Molecular Life Sciences.

[86]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[87]  H. Kim,et al.  Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration , 2010, Journal of tissue engineering.

[88]  Christian Wiesmann,et al.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. , 2009, The Journal of clinical investigation.

[89]  Hiroyuki Tanaka,et al.  FGFR3-related dwarfism and cell signaling , 2009, Journal of Bone and Mineral Metabolism.

[90]  B. Trueb,et al.  The cell surface receptor FGFRL1 forms constitutive dimers that promote cell adhesion. , 2008, Experimental cell research.

[91]  H. Tenenhouse,et al.  Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. , 2007, American journal of physiology. Renal physiology.

[92]  M. Knowles,et al.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer , 2007, The Journal of pathology.

[93]  M. Knowles,et al.  Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer , 2007, Oncogene.

[94]  Daryl A. Scott,et al.  Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development , 2007, Development.

[95]  Shaun K Olsen,et al.  Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.

[96]  B. Thisse,et al.  Functions and regulations of fibroblast growth factor signaling during embryonic development. , 2005, Developmental biology.

[97]  J. Casal,et al.  Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation , 2005, Clinical Cancer Research.

[98]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[99]  V. P. Eswarakumar,et al.  Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.

[100]  D. Ambrosetti,et al.  Mechanisms underlying differential responses to FGF signaling. , 2005, Cytokine & growth factor reviews.

[101]  M. Knowles,et al.  Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. , 2005, Experimental cell research.

[102]  S. Santa Cruz,et al.  Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[103]  Walter Birchmeier,et al.  The Docking Protein Gab1 Is an Essential Component of an Indirect Mechanism for Fibroblast Growth Factor Stimulation of the Phosphatidylinositol 3-Kinase/Akt Antiapoptotic Pathway , 2004, Molecular and Cellular Biology.

[104]  Michael Tsang,et al.  Promotion and Attenuation of FGF Signaling Through the Ras-MAPK Pathway , 2004, Science's STKE.

[105]  N. Cross,et al.  Critical Role of STAT5 Activation in Transformation Mediated by ZNF198-FGFR1* , 2004, Journal of Biological Chemistry.

[106]  S. Burchill,et al.  FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells , 2003, British Journal of Cancer.

[107]  I. Lax,et al.  The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. , 2002, Molecular cell.

[108]  P. Marie,et al.  FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. , 2002, Genes & development.

[109]  I. Lax,et al.  FRS2α attenuates FGF receptor signaling by Grb2- mediated recruitment of the ubiquitin ligase Cbl , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[110]  R. Adar,et al.  Differential Activation of Cysteine‐Substitution Mutants of Fibroblast Growth Factor Receptor 3 Is Determined by Cysteine Localization , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[111]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[112]  S C Robertson,et al.  Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. , 2001, Molecular biology of the cell.

[113]  A. N. Meyer,et al.  Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4 , 2000, Oncogene.

[114]  Z. Vajo,et al.  The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. , 2000, Endocrine reviews.

[115]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[116]  D. Ornitz,et al.  FGF signaling in skeletal development. , 1998, Frontiers in bioscience : a journal and virtual library.

[117]  I. Lax,et al.  Binding of Shp2 Tyrosine Phosphatase to FRS2 Is Essential for Fibroblast Growth Factor-Induced PC12 Cell Differentiation , 1998, Molecular and Cellular Biology.

[118]  D. Bar-Sagi,et al.  A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras/MAPK Signaling Pathway , 1997, Cell.

[119]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[120]  Gary W. Harding,et al.  Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 , 1996, Nature Genetics.

[121]  P. Leder,et al.  Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth , 1996, Cell.

[122]  M. Jaye,et al.  Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction , 1996, Molecular and cellular biology.

[123]  D. Donoghue,et al.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.

[124]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[125]  S. Werner,et al.  Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities , 1992, Molecular and cellular biology.

[126]  M. Jaye,et al.  A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1 , 1991, Molecular and cellular biology.

[127]  S. Werner,et al.  Immunoglobulin Domain. Receptor Forms That Differ in Their Third Underlies the Mechanisms for Generating Genes: a Common Structural Arrangement the Human Fibroblast Growth Factor Receptor , 1990 .